Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Calliditas Therapeutics Ab ADR (CALT)

Calliditas Therapeutics Ab ADR (CALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,195,175
  • Shares Outstanding, K 29,790
  • Annual Sales, $ 113,810 K
  • Annual Income, $ -43,960 K
  • 60-Month Beta 1.77
  • Price/Sales 10.67
  • Price/Cash Flow N/A
  • Price/Book 121.02
Trade CALT with:

Options Overview Details

View History
  • Implied Volatility 15.71% ( -5.46%)
  • Historical Volatility 12.78%
  • IV Percentile 3%
  • IV Rank 3.54%
  • IV High 139.57% on 04/18/24
  • IV Low 11.16% on 07/10/24
  • Put/Call Vol Ratio 0.67
  • Today's Volume 5
  • Volume Avg (30-Day) 15
  • Put/Call OI Ratio 1.64
  • Today's Open Interest 648
  • Open Int (30-Day) 569

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.10
  • Number of Estimates 4
  • High Estimate 0.12
  • Low Estimate -0.36
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +82.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.77 +12.16%
on 08/15/24
41.50 -3.33%
on 08/26/24
+2.02 (+5.30%)
since 07/30/24
3-Month
35.77 +12.16%
on 08/15/24
41.90 -4.25%
on 06/06/24
+1.65 (+4.28%)
since 05/30/24
52-Week
15.25 +163.08%
on 11/13/23
41.90 -4.25%
on 06/06/24
+23.31 (+138.67%)
since 08/29/23

Most Recent Stories

More News
Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

/PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a...

CALT : 40.12 (-0.99%)
European Medicines Agency Committee for Orphan Medicinal Products provides positive opinion on Calliditas' application for setanaxib in Alport syndrome

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the European Medicines Agency (EMA)...

CALT : 40.12 (-0.99%)
Everest Medicines' Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023

/PRNewswire/ -- Everest Medicines' (HKEX 1952.HK, "Everest", or the "Company") partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX)...

CALT : 40.12 (-0.99%)
Calliditas announces filing with UK MHRA for Kinpeygo in IgA nephropathy

/PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announced that its partner STADA Arzneimittel AG ("STADA") has...

CALT : 40.12 (-0.99%)
Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023

/PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced the presentations of new biomarker and...

CALT : 40.12 (-0.99%)
STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU

Request submitted by STADA to EMA to convert conditional marketing authorization to standard marketing authorization for Kinpeygo treatment for primary IgA...

CALT : 40.12 (-0.99%)
Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the US Food and Drug Administration...

CALT : 40.12 (-0.99%)
Why Shares of Calliditas Therapeutics Are Rising Thursday

The company's shares rose in response to a competitors' mixed phase 3 trial.

CALT : 40.12 (-0.99%)
Calliditas Therapeutics to Present Nefecon Data at the 17th International Symposium on IgA Nephropathy (IIgANN) September 25-27 in Tokyo

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), today announced upcoming data presentations from the...

CALT : 40.12 (-0.99%)
Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon® for the Treatment of IgA Nephropathy

/PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced today that U.S. Food and Drug Administration (FDA) has accepted the...

CALT : 40.12 (-0.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Calliditas Therapeutics AB is a specialty pharmaceutical company. It is focused on developing pharmaceutical products for patients with a significant unmet medical need. The compnay's lead candidate consist Nefecon. Calliditas Therapeutics AB is based in Stockholm, Sweden.

See More

Key Turning Points

3rd Resistance Point 40.73
2nd Resistance Point 40.43
1st Resistance Point 40.28
Last Price 40.12
1st Support Level 39.83
2nd Support Level 39.53
3rd Support Level 39.38

See More

52-Week High 41.90
Last Price 40.12
Fibonacci 61.8% 31.72
Fibonacci 50% 28.58
Fibonacci 38.2% 25.43
52-Week Low 15.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar